The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion.
Christoper Hooper, Matthew Anderson, Sarah Bowen Jones et al.
✦ AI-curated · Sources linked
Case in brief
This article presents four case studies of patients with inoperable stage III non-small cell lung cancer discussed at a UK academic webinar. The cases illustrate treatment challenges related to tumour features, including vascular invasion and bulky disease, and patient factors such as interstitial lung disease, multiple comorbidities and frailty. These factors can make concurrent chemoradiotherapy and subsequent durvalumab unsuitable or difficult to tolerate. The discussion describes radiotherapy-based strategies for navigating these complexities, while noting that evidence to guide care for patients ineligible for standard treatment remains limited.
What made this case unusual
The cases bring together both tumour-related and patient-related barriers to standard treatment, including vascular invasion, bulky disease, interstitial lung disease and frailty, to discuss radiotherapy-based management in complex patients.
Diagnostic / clinical pearl
Assess tumour characteristics and comorbidities alongside fitness when considering treatment for stage III NSCLC; patients unable to receive standard concurrent therapy are a group for whom evidence remains limited.
Why it matters
The authors highlight broader trial eligibility and inclusive research as ways to build safety and efficacy evidence for patients currently under-represented in practice-defining trials.